30 July 2012 Australia (Kamagrarx.co) : Merck, one of the well-known pharmaceutical giant has added another quill to its wide range
of effective medications by completing phase III clinical trials of a new drug responsible for
inducing sleep in patients suffering from insomnia.
The pharma company is currently awaiting the approval of this sleep drug known as suvorexant
by the FDA (Food and Drug Administration) at least by the end of this year.
As per the latest available clinical data related to the phase III experimental analysis is that the
drug proved to be successful in inducing sleep in patients suffering from insomnia in an effective
and safe way. This drug is believed to be the largest late-stage treatment perspectives in the
pipeline of the company.
The medication has been found to emerge as a winner of 15 statistical bars out the total 16,
which it lost to the placebo that was found to provide continuous sleep faster than the drug after
the treatment course of three months.
Darryle D. Schoepp, head of the neuroscience and ophthalmology of Merck Research
Laboratories said that the company has a wide range of late-stage information on the drug
suvorexant to prove that it works marvelously and also, possess the potential to prove effective
even on long term treatment.
He also claimed that the main USP (Unique Selling Point) of the drug is that despite being safe
and inducing sleep quickly, around 90 % of patients cleared showed that the feel of drowsiness
did not occur the day after the drug was taken. And this point is believed to a unique and
remarkable feat of this medication that can take it a long way in the clinical world.
Andrew D. Krystal, M.D., a professor of behavioral sciences and psychiatry at a medical center
claimed that this novel and unique drug may get a warm welcome from patients all over the
world suffering from insomnia.
Kamagrarx.co
100 Railway Street
Sydney, NSW, AUSTRALIA- 2766
For more: http://www.kamagrarx.co
http://www.kamagrarx.co/kamagra-jelly.html